CONDUCTION
ABNORMALITIES/
PACEMAKERS
INTOLERANCE
TO BLOOD PRESSURE MEDICATIONS
-
SENSORIMOTOR NEUROPATHY
-
CARDIAC
-
MUSCULOSKELETAL
-
AUTONOMIC DYSFUNCTION
-
NEPHROPATHY
-
CO-MORBIDITIES
-
OTHER SYMPTOMS
SENSORIMOTOR NEUROPATHY1-3

Painful neuropathy in hands and feet

Muscle weakness, difficulty walking, and falls
CARDIAC1-3

Heart failure

Atrial fibrillation

Bradyarrhythmias/ conduction abnormalities/ pacemakers
MUSCULOSKELETAL1-3

Back pain/lumbar spinal stenosis

Ruptured biceps tendon/Popeye sign

Shoulder, knee, and hip pain or surgery

Trigger finger

Bilateral carpal tunnel syndrome
AUTONOMIC DYSFUNCTION1-3

Orthostatic hypotension/ intolerance to blood pressure medications

Chronic diarrhea/ constipation/weight loss

Erectile dysfunction
NEPHROPATHY1-3

Proteinuria

Renal failure
CO-MORBIDITIES
OTHER SYMPTOMS

Carpal tunnel syndrome

Severe fatigue

An enlarged tongue, which sometimes looks rippled around its edge

Eye involvement (e.g., vitreous opacities)

Shortness of breath
References: 1. Nativi‑Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785-793. 2. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107-S112. 3. Adams D, Algalarrondo V, Polydefkis M, Sarswat N, Slama MS, Nativi-Nicolau J. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021;16(1):411. 4. Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):198. 5. Bazell C, Alston M, Kumar N, et al. Descriptive characteristics of patients diagnosed with transthyretin amyloidosis (ATTR) in the Medicare fee-for-service and commercial populations [abstract and poster]. International Symposium of Amyloidosis; May 26-30, 2024; Rochester, MN. 6. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658-2667. 7. Conceição I, González-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9. 8. Kittleson MM, Ruberg FL, Ambardekar AV, et al; Writing Committee. 2023 ACC Expert Consensus Decision Pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076-1126.
